

Emir Hadzijusufovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1153434/publications.pdf>

Version: 2024-02-01

71
papers

1,987
citations

279487

23
h-index

253896

43
g-index

71
all docs

71
docs citations

71
times ranked

2576
citing authors

#	ARTICLE	IF	CITATIONS
1	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	3.3	29
2	Hereditary β -tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. <i>Blood</i> , 2021, 137, 238-247.	0.6	113
3	<i>In vitro</i> effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells. <i>Veterinary Medicine and Science</i> , 2021, 7, 57-68.	0.6	6
4	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	2.0	13
5	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1719-1727.	0.3	14
6	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. <i>Blood</i> , 2021, 138, 1481-1481.	0.6	6
7	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. <i>Frontiers in Veterinary Science</i> , 2021, 8, 755258.	0.9	16
8	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6181.	1.7	1
9	PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.. <i>American Journal of Cancer Research</i> , 2021, 11, 6042-6059.	1.4	0
10	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	4.6	107
11	STAT5 is Expressed in CD34+/CD38 ^{low} Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	1.7	12
12	Overexpression of PD-L1 Correlates with JAK2-V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN. <i>Blood</i> , 2020, 136, 24-24.	0.6	3
13	History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299.		0
14	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 1-10.	0.8	18
15	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. <i>Veterinary and Comparative Oncology</i> , 2019, 17, 553-561.	0.8	13
16	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	2.2	101
17	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	2.0	42
18	A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. <i>Leukemia Research</i> , 2019, 78, 36-44.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Cover Image, Volume 16, Issue 1. <i>Veterinary and Comparative Oncology</i> , 2018, 16, i.	0.8	0
20	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica</i> , 2018, 103, 799-809.	1.7	30
21	Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. <i>Leukemia</i> , 2018, 32, 1016-1022.	3.3	20
22	The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 55-68.	0.8	19
23	Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. <i>Experimental Hematology</i> , 2018, 57, 50-59.e6.	0.2	16
24	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.0	3
25	Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. <i>Leukemia</i> , 2017, 31, 788-797.	3.3	37
26	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. <i>Leukemia Research</i> , 2017, 59, 47-54.	0.4	58
27	Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. <i>Leukemia</i> , 2017, 31, 2388-2397.	3.3	110
28	IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 1240-1256.	0.8	8
29	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. <i>Oncotarget</i> , 2017, 8, 23061-23072.	0.8	13
30	Comparing Human Breast Cancer with Canine Mammary Cancer. , 2017, , 191-207.		0
31	Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. <i>Leukemia</i> , 2016, 30, 464-472.	3.3	48
32	Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. <i>Blood</i> , 2016, 128, 1883-1883.	0.6	9
33	The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 1965-1965.	0.6	11
34	Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry). <i>Blood</i> , 2016, 128, 396-396.	0.6	4
35	Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. <i>Blood</i> , 2015, 125, 901-906.	0.6	239
36	Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. <i>Blood</i> , 2015, 126, 2832-2841.	0.6	47

#	ARTICLE	IF	CITATIONS
37	Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. <i>Leukemia</i> , 2015, 29, 2230-2237.	3.3	21
38	Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells. <i>Blood</i> , 2015, 126, 2829-2829.	0.6	0
39	Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R. <i>PLoS ONE</i> , 2014, 9, e84417.	1.1	15
40	Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. <i>Haematologica</i> , 2014, 99, 417-429.	1.7	50
41	The <i>KIT</i> allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 810-813.	2.7	86
42	A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. <i>Blood</i> , 2014, 124, 111-120.	0.6	80
43	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. <i>Blood</i> , 2014, 124, 1800-1800.	0.6	5
44	Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. <i>Oncotarget</i> , 2014, 5, 1198-1211.	0.8	19
45	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 114-118.	0.3	0
46	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. <i>Haematologica</i> , 2013, 98, 1450-1457.	1.7	39
47	The pan-Bcl-2 blocker obatoclox promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. <i>Journal of Leukocyte Biology</i> , 2013, 95, 95-104.	1.5	32
48	Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms. <i>Blood</i> , 2013, 122, 3747-3747.	0.6	1
49	Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis. <i>Blood</i> , 2013, 122, 3773-3773.	0.6	1
50	KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease. <i>Blood</i> , 2013, 122, 4052-4052.	0.6	0
51	Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). <i>American Journal of Blood Research</i> , 2013, 3, 174-80.	0.6	16
52	5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. <i>Blood</i> , 2012, 119, 4242-4252.	0.6	41
53	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.0	33
54	<i>NI</i> : a novel canine mastocytoma model for studying drug resistance and <i>IL</i> -dependent mast cell activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 858-868.	2.7	18

#	ARTICLE	IF	CITATIONS
55	The PI3-Kinase/mTOR-Targeting Drug NVP-BE2235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils. <i>PLoS ONE</i> , 2012, 7, e29925.	1.1	24
56	KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. <i>Blood</i> , 2011, 118, 1885-1898.	0.6	64
57	Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. <i>Haematologica</i> , 2011, 96, 672-680.	1.7	17
58	The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release. <i>Blood</i> , 2011, 118, 1417-1417.	0.6	1
59	Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML. <i>Blood</i> , 2011, 118, 2753-2753.	0.6	6
60	Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis. <i>Blood</i> , 2011, 118, 3497-3497.	0.6	1
61	5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells. <i>Blood</i> , 2011, 118, 3457-3457.	0.6	0
62	KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). <i>Experimental Hematology</i> , 2010, 38, 782-791.	0.2	10
63	H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. <i>Experimental Hematology</i> , 2010, 38, 896-907.	0.2	35
64	Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. <i>Cancer Research</i> , 2010, 70, 1513-1523.	0.4	86
65	The Aurora-Kinase Inhibitor R763/AS703569 Exerts Major Growth-Inhibitory and Apoptosis-Inducing Effects on Neoplastic Mast Cells. <i>Blood</i> , 2010, 116, 3972-3972.	0.6	3
66	Establishment of a Novel Canine Mastocytoma Cell Line, NI-1: a Model for Studying Resistance Against KIT Tyrosine Kinase Inhibitors In Canine Neoplastic Mast Cells. <i>Blood</i> , 2010, 116, 4936-4936.	0.6	0
67	Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. <i>Veterinary Immunology and Immunopathology</i> , 2009, 132, 243-250.	0.5	17
68	Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementary Material). <i>Current Cancer Drug Targets</i> , 2009, 9, 675-689.	0.8	21
69	Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature. <i>In Vivo</i> , 2009, 23, 911-8.	0.6	7
70	Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. <i>Experimental Hematology</i> , 2008, 36, 1461-1470.	0.2	19
71	Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. <i>Experimental Hematology</i> , 2007, 35, 1510-1521.	0.2	50